Peripheral atherectomy — the endovascular plaque removal or modification devices providing directional, laser, rotational, and orbital atherectomy for calcified peripheral artery lesions that resist angioplasty alone — creates the specialty device market for complex peripheral vascular intervention, with the Peripheral Angioplasty Market reflecting atherectomy as a significant and growing peripheral intervention market segment.

Laser atherectomy and the Spectranetics/Philips CVX-300 — the excimer laser coronary atherectomy system adapted for peripheral use providing photoablation of calcified and fibrotic plaque — represents the established laser atherectomy platform for complex below-knee lesions and in-stent restenosis. Philips Stellarex DCB combined with laser atherectomy (the EXCITE-ISR trial data) demonstrates the synergistic combination approach for in-stent restenosis management.

Orbital atherectomy cardiovascular system — the Cardiovascular Systems Inc. (Diamondback 360) orbital atherectomy system using differential orbital motion of a diamond-coated crown to sand calcium deposits from artery walls — provides the calcium modification that enables balloon angioplasty in severely calcified peripheral arteries that would otherwise balloon rupture or fail to dilate. CSI Diamondback's FDA clearance for peripheral artery atherectomy and subsequent expansion into coronary applications demonstrates the technology's versatility.

Directional atherectomy TurboHawk — the Medtronic TurboHawk directional atherectomy system excising and removing plaque from one side of the vessel without treating the entire circumference — provides targeted plaque removal for eccentric lesions. Directional atherectomy's advantage for plaque-heavy lesions requiring debulking before drug delivery represents the specific niche where TurboHawk and similar devices provide clinical value beyond balloon and stent approaches alone.

Do you think atherectomy devices provide sufficient incremental clinical benefit over DCB angioplasty alone to justify their significantly higher cost for most peripheral artery lesion types?

FAQ

What is orbital atherectomy and how does it treat calcification? Orbital atherectomy (Cardiovascular Systems Diamondback 360) uses a diamond-coated eccentric crown attached to a drive shaft that rotates and orbits within the vessel at approximately eighty thousand to two hundred thousand RPM; the eccentric orbital motion creates a channel larger than the crown diameter (up to two-point-three mm crown treating three-to-four-plus millimeter artery); the abrasive diamond crown sands calcified plaque deposits, differentially ablating hard calcium while flexible tissue deflects away; creates microfractures and removes calcium creating compliant vessel walls that respond better to balloon dilation; saline infusion removes debris; vessel treated by crossing lesion multiple times with increasing crown orbit; FDA cleared for peripheral artery (FDA-cleared 2004) and coronary artery (ORBIT II study) applications.

When is atherectomy indicated for peripheral artery disease? Atherectomy indications include: moderate-to-severe calcification preventing adequate balloon expansion or stent deployment, in-stent restenosis (particularly laser atherectomy for removing fibrous neointimal tissue), below-the-knee lesions where stent placement is suboptimal, long diffuse calcified lesions requiring debulking before drug delivery, and lesions in anatomically challenging locations (popliteal bifurcation, tibial vessels) where stent placement would compromise branch vessels; evidence level is lower for atherectomy than for DCB/DES from limited large RCT data; DEFINITIVE LE trial supported directional atherectomy in SFA and popliteal arteries; clinical decision driven by lesion characteristics, operator experience, and lesion access; added cost requires selective application for lesions most likely to benefit.

#PeripheralAngioplasty #Atherectomy #OrbitalAtherectomy #LaserAtherectomy #PeripheralCalcification #DiamondbackPeripheral